{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:37:10Z","timestamp":1791023830375,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH"},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["MH083689"],"award-info":[{"award-number":["MH083689"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIDA","award":["DA02189"],"award-info":[{"award-number":["DA02189"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.neuropharm.2011.02.006","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T13:55:51Z","timestamp":1298555751000},"page":"503-512","source":"Crossref","is-referenced-by-count":57,"title":["An animal model of schizophrenia based on chronic LSD administration: Old idea, new results"],"prefix":"10.1016","volume":"61","author":[{"given":"Danuta","family":"Marona-Lewicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.02.006_bib1","first-page":"1","article-title":"Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors","author":"Bortolozzi","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00008877-199902000-00006","article-title":"The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function","volume":"10","author":"Dall\u2019Olio","year":"1999","journal-title":"Behav. Pharmacol"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02245611","article-title":"Inhibitory effects on the discriminative stimulus properties of d-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?","volume":"124","author":"Arnt","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0893-133X(02)00376-7","article-title":"The effects of excitocic hippocampal lesions in rats on resperidone- and olanzapine-induced locomotor suppression","volume":"27","author":"Bardgett","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-010-1938-0","article-title":"Validation and pharmacological characterizataion of MK-801-induced locomotor hyperactivity in BALB\/C mice as an assay for detection of novel antipsychotics","volume":"212","author":"Bradford","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0006-3223(03)00526-2","article-title":"Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis","volume":"54","author":"Castensson","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0091-3057(86)90371-0","article-title":"Hallucinogenic drug research -If so, so what?: symposium summary and commentary","volume":"24","author":"Freedman","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0306-4530(02)00049-5","article-title":"Olanzapine\u2019s effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats","volume":"28","author":"Frye","year":"2003","journal-title":"Psychoneuroendocrynology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/nn0110-2","article-title":"Testing the glutamate hypothesis of schizophrenia","volume":"13","author":"Gordon","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J.\u00a0Psychedelic Drugs"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib11","article-title":"Developing new drugs in schizophrenia: from animals to the clinic","volume":"Vol 1","author":"Jones","year":"2008"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02976533","article-title":"NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice","volume":"22","author":"Kim","year":"1999","journal-title":"Arch. Pharm.Res."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/0269881107077712","article-title":"Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?","volume":"21","author":"Large","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A\u00a0simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90051-5","article-title":"Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan","volume":"258","author":"Marona-Lewicka","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pbb.2007.06.001","article-title":"Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action","volume":"87","author":"Marona-Lewicka","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","article-title":"Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis","volume":"180","author":"Marona-Lewicka","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-008-1238-0","article-title":"Dopamine D(4) receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI","volume":"203","author":"Marona-Lewicka","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-2999(97)01351-4","article-title":"Olanzapine attenuates the reinforcing effects of cocaine","volume":"340","author":"Meil","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib20","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.brainres.2004.07.044","article-title":"Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex","volume":"1023","author":"Muschamp","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"Nichols","year":"2004","journal-title":"Hallucinogens. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0893-133X(01)00405-5","article-title":"A\u00a0single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain","volume":"26","author":"Nichols","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1471-4159.2004.02515.x","article-title":"Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C\/EBP-beta and ILAD-1, a novel gene with homology to arrestins","volume":"90","author":"Nichols","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0169-328X(03)00029-9","article-title":"Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration","volume":"111","author":"Nichols","year":"2003","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib26","series-title":"Psycholytic and Psychedelic Therapy Research: a Complete International Bibliography 1931-1995","author":"Passie","year":"1997"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.npp.1300127","article-title":"Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine","volume":"28","author":"Takahata","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0169-328X(00)00293-X","article-title":"Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex","volume":"87","author":"Tallerico","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib29","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.biopsych.2005.04.041","article-title":"Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study","volume":"58","author":"van Elst","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","article-title":"A\u00a0systems model of altered consciousness: integrating natural and drug-induced psychoses","volume":"56","author":"Vollenweider","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0024-3205(00)00934-6","article-title":"Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between the glutamatergic and serotonergic hypothesis of schizophrenia","volume":"68","author":"Winter","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2011.02.006_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-003-1636-2","article-title":"Serotonergic\/glutamatergic interactions: the effects of mGlu2\/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli","volume":"172","author":"Winter","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2011.02.006_bib34","series-title":"Biostatistical Anaysis","author":"Zar","year":"1999"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:26:17Z","timestamp":1740957977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390811000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0028390811000682"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.006","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}